Glenmark Pharma is currently trading at Rs. 280.00, up by 0.25 points or 0.09% from its previous closing of Rs. 279.75 on the BSE.
The scrip opened at Rs. 281.15 and has touched a high and low of Rs. 282.40 and Rs. 278.05 respectively. So far 8565 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 372.10 on 06-Jan-2011 and a 52 week low of Rs. 241.60 on 28-Feb-2011.
Last one week high and low of the scrip stood at Rs. 284.90 and Rs. 267.10 respectively. The current market cap of the company is Rs. 7571.80 crore.
The promoters holding in the company stood at 48.29% while Institutions and Non-Institutions held 39.02% and 12.69% respectively.
Glenmark Pharmaceuticals has obtained the DCGI (India) approval to conduct the pivotal study of Crofelemer in Acute Watery Diarrhoea patients. Post approval from the DCGI, dosing in patients has also commenced. This is a randomized, double blinded, placebo controlled, parallel Group, three arm, multicenter and multinational pivotal study that is being carried out to assess the Efficacy and Safety of two dosage regimens of Crofelemer Tablets in the Treatment of Moderate to Severe Acute Watery Diarrhoea in Adult Patients including cholera. This Phase III study will be done at leading centres in India and Bangladesh.
Glenmark Pharmaceuticals has an exclusive license from Napo Pharmaceuticals, Inc. to distribute and commercialize Crofelemer in 140 emerging countries (rest of world territories) including India for indications related to HIV, use in acute adult and pediatric diarrhoea.
Crofelemer is a novel, first-in-class anti-diarrhoeal agent that has a physiological and different mechanism of action from traditional anti-diarrhoeal agents. Besides its potential efficacious role in multiple diarrhoeal indications, Crofelemer controls diarrhoea with no drug-drug interactions, minimal systemic adsorption and, unlike current antidiarrhoeals, no serious side effects.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1777.65 |
| Dr. Reddys Lab | 1194.55 |
| Cipla | 1465.65 |
| Lupin | 2043.30 |
| Zydus Lifesciences | 944.25 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Claim your FREE 15-day access to the most practical investing handbook.
Hurry, limited to the first 10 users today!
FREE Become a savvy and confident
stock investor.
Hurry, limited to the first 10 users today!
Download APP
